iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by AnalystsMarket Beat·Aug 9 at 03:14 AMIBIO-1.38%STT-0.71%
Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target MaintainedTip Ranks·Jul 1 at 02:15 PMIBIO-1.38%
iBio shares are trading higher after the company announced that a single dose of its IBIO-610 treatment lowered levels of metabolism regulator protein Activin E in primates for up to 8 weeks.benzinga_article·Jul 1 at 09:38 AMIBIO-1.38%
iBio says single-dose IBIO-610 cuts active Activin E 98% through eight weeks in obese primate studyPUBT·Jul 1 at 06:02 AMIBIO-1.38%
iBio to Participate in Upcoming Healthcare Investor Conferences | IBIO Stock NewsStockTitan·Jun 2 at 07:01 AMIBIO-1.38%
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with ObesityUnusual Whales·Jun 2 at 06:02 AMIBIO-1.38%
Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)Tip Ranks·May 15 at 10:28 AMIBIO-1.38%BBH+1.24%
